OTLK · Outlook Therapeutics, Inc.
$0.64
+0.02 (+2.86%)
At close · Aug 27
Going-concern doubt
— flagged Aug 18, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We evaluated whether there are conditions or events considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern. We do not believe that the existing cash and cash equivalents, together with net proceeds of $51.1 million from the August 2026 Offering, as of June 30, 2026 are sufficient to fund the Company's operations through one year from the date of this Quarterly Report on Form 10-Q. As a result, there is substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 18, 2026
Market Cap
$157.07M
Shares
243.45M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Key facts
CIK
1649989
CUSIP
69012T305
13F (30d)
59 filings
59 filers
Visit website
Investor relations